Contribute Try STAT+ Today
Trending:
Coronavirus
Pharmalot
First Opinion
Biotech
The Readout

Moderna’s patent problems & clocking the CRISPR race

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan May 17, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for May 17, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana covers biotech and contributes to The Readout newsletter.

Trending
With a nudge from AI, ketamine emerges as a…
With a nudge from AI, ketamine emerges as a potential rare disease treatment
tossing face mask
How the Covid pandemic ends: Scientists look to the…
How the Covid pandemic ends: Scientists look to the past to see the future
vaccine silhouette
Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and…
Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson
Recommended
The READOUT
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The READOUT
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The READOUT
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

More in The Readout

The READOUT
The Readout

Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs

By Meghana Keshavan

The READOUT
The Readout

Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue

By Damian Garde

The READOUT
The Readout

Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

By Damian Garde

The READOUT
The Readout

How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

By Damian Garde

The READOUT
The Readout

Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement

By Meghana Keshavan